TABLE 8.
Comparison of healthy participants and COPD patient concentration of RIBAVIRIN in plasmaa
| Treatment group, dose | PK parameter (units) | N | n | Visit (day) | Geometric mean | 95% CI | %CVb |
|---|---|---|---|---|---|---|---|
| BID, 60 mg (HV) | Cmax (ng/ml) | 12 | 12 | 1 | 189 | 130–273 | 63.5 |
| 11 | 14 | 285 | 221–367 | 39.0 | |||
| AUC0–τ (h.ng/ml) | 12 | 12 | 1 | 565 | 418–763 | 50.2 | |
| 8 | 14 | 2,060 | (1,815, 2,337) | 15.2 | |||
| BID, 60 mg (COPD) | Cmax (ng/ml) | 8 | 8 | 1 | 178 | 119–267 | 51.4 |
| 8 | 14 | 423 | 326–549 | 31.9 | |||
| AUC0–τ (h.ng/ml) | 8 | 8 | 1 | 687 | 499–947 | 39.8 | |
| 7 | 14 | 3,087 | (2,393, 3,982) | 28.1 |
a
N, total number of participants; n, number of participants with observations.